INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies—Established Findings and Future Priorities

Keyphrases

• Chimeric Antigen Receptor T Cells (CAR-T) 100%
• Chimeric Antigen Receptor T-cell Therapy 100%
• Clinical Trials 40%
• Recent Advances 20%
• Tumor 20%
• National Institutes of Health 20%
• Solid Tumors 20%
• Tumor Microenvironment 20%
• Pediatric 20%
• B-cell Malignancies 20%
• Intrinsic Properties 20%
• Immune-related Adverse Events 20%
• Maryland 20%
• Cell Manufacturing 20%
• Regulatory Agencies 20%
• Active Area 20%
• Tumor Stroma 20%
• Cellular Products 20%
• Immunosuppressive Cells 20%
• Bethesda 20%
• Treatment Resistance 20%
• Lymphodepletion 20%
• Immunotherapy Resistance 20%
• Treatment Durability 20%

Medicine and Dentistry

• Chimeric Antigen Receptor T-Cell Immunotherapy 100%
• Chimeric Antigen Receptor T-Cell 100%
• Neoplasm 40%
• Clinical Trial 40%
• Biological Marker 20%
• Pediatrics 20%
• Solid Malignant Neoplasm 20%
• Cancer 20%
• B Cell 20%
• Stroma 20%
• Tumor Microenvironment 20%
• Immune-Related Adverse Events 20%

Immunology and Microbiology

• Chimeric Antigen Receptor T-Cell 100%
• Chimeric Antigen Receptor T-Cell Therapy 50%
• Immunotherapy 33%
• Stroma 16%
• B Cell 16%